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Abstract
Background: TARDBP mutations have been reported in patients with amyotrophic lateral sclerosis (ALS) in different
populations except Chinese. The present aim is to investigate the association between TARDBP mutations and
Chinese patients with ALS.
Methods: 71 SALS patients and 5 FALS families with non-SOD1 mutations were screened for TARDBP mutations via
direct sequencing.
Results: A novel heterozygous variation, Ser292Asn (875G>A), was identified in the proband and 4 asymptomatic
relatives including the children of the dead patient from a FALS family. Thus the dead patient, the proband’s
brother, was speculated to carry Ser292Asn though his sample was unavailable to the detection. This variation was
not found in 200 unrelated control subjects. A homology search of the TDP-43 protein in different species
demonstrated that it was highly conserved. Also, it was predicted to be deleterious to protein function with SIFT-
calculated probabilities of 0.00. Therefore, Ser292Asn is predicted to be a pathogenic mutation. In addition, we
have found two silent mutations (Gly40Gly and Ala366Ala) and one novel polymorphism (239-18t>c).
Conclusions: The present data have extended the spectrum of TARDBP mutations and polymorphisms, and
supported the pathological role of TDP-43 in Chinese ALS patients.
Background
Amyotrophic lateral sclerosis (ALS) is the most com-
mon form of motor neuron disease and is characterized
by progressive loss of upper and lower motor neurons
from the spinal cord, brain stem and cerebral cortex,
leading to paralysis and eventually death which is due to
respiratory failure within 3-5 years after symptom onset
[1]. Approximately 5-10% of ALS cases are familial
(FALS) whereas the remaining patients are sporadic
(SALS) [2]. About 15-20% of patients with autosomal
dominant FALS have mutations in the copper-zinc
superoxide dismutase 1 gene (SOD1), while mutations
in other genes including alsin (ALS2), senataxin (SETX,
ALS4), dynactin (DCTIN1), angiogenin (ANG),
synaptobrevin-associated membrane protein B (VAPB,
ALS8) and Fused in Sarcoma (FUS, ALS6) are described
as rare causes of FALS [2-5]. Recently, a novel senataxin
mutation has been reported in a SALS patient [6]. Ubi-
quitin-positive tau-negative neuronal cytoplasmic inclu-
sion is the common pathological feature in
frontotemporal lobar degeneration (FTLD) and ALS.
TAR DNA-binding protein 43 (TDP-43), which is a
414-amino-amino-acid nuclear protein encoded by
TARDBP on chromosome 1p36.22, was recognized as a
major constituent of these neuronal cytoplasmic inclu-
sions [7,8]. To date, a total of 30 TARDBP mutations
have been reported in ALS patients [9-20]. These muta-
tions affect the C-terminal region of TDP-43 and may
influence protein-protein interaction, exon skipping and
splicing inhibitory activity, thus, may influence the
proper function or transport of TDP-43. Here, we first
reported the screen for TARDBP mutations in Chinese
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mutation, two silent mutations and one novel
polymorphism.
Methods
Subjects
Seventy-one unrelated SALS patients and probands from
5 FALS families with non-SOD1 mutations from the
Han ethnic group were enrolled in our study between
12 December 2007 and 3 March 2009 from department
of Neurology at Huashan Hospital. Of them, 56 were
males and 20 were females, and the average age of
symptom onset was 52 years (range, 32-76 years). All
patients had been examined by at least two neurologists.
Neurological examinations including electromyography
(EMG) and magnetic resonance imaging (MRI) of the
cervical cord were performed. Medical history and
demographic information were collected by a specially-
assigned person, and records were reviewed by two
senior neurologists. All patients were diagnosed as defi-
nite ALS according to the Airlie House criteria [21]. 16
patients presented with bulbar-onset disease and 60
patients presented with spinal-onset disease. Two hun-
dred unrelated aged individuals (≥60 years) consisted of
100 men and 100 women with no known history of ALS
were selected as a control group. All of them are Han
people from Southern China. This study was approved
by the local ethics committee, and informed consent
was obtained from the participants or their legal surro-
gates prior to inclusion in the study. Genomic DNA was
extracted from peripheral EDTA blood with a TIANamp
Blood DNA kit (TIANGEN Biotech, Beijing).
Mutation scanning
The coding region of TARDBP, exons 2-6, including the
intron-exon boundaries, were analyzed using primer com-
binations designed based on the intronic sequences of
TARDBP. PCR amplification was performed using a Gen-
eAmp PCR system 9700 (Applied Biosystems, Foster City,
CA, USA) with standard conditions. The sequence of the
primers and the annealing temperatures are shown in the
Table 1. Amplified products were purified and subjected
to direct sequencing, and the procedure is as previously
reported [22]. Obtained sequences were compared with
the genomic DNA sequence of TARDBP (NCBI Sequence
Viewer NT_021937.18), and nucleotide changes were
numbered corresponding to their position in TARDBP
mRNA (NCBI Sequence Viewer NM_007375.3).
Results
Mutations and polymorphisms of TARDBP gene identified
in the present study
After screening mutations of TARDBP in 5 FALS
patients and 71 SALS patients, a heterozygous variation
Ser292Asn (875G>A) which has not been reported
previously was identified in a FALS patient. The chro-
matogram is shown in figure 1A. This variation was not
found in 200 unrelated control subjects, reducing the
likelihood that it represents a polymorphism. Moreover,
a homology search of the TDP-43 protein in different
species demonstrated that this variation was highly con-
served (figure 1B). At the same time, the program SIFT
(Sorting Intolerant From Tolerant) [23] has been applied
to predict whether this sequence change could affect
protein function, and it was predicted to be deleterious
to protein function with SIFT-calculated probabilities of
0.00, thus Ser292Asn is a novel mutation and most
probably a pathogenic one.
In addition, two silent mutations, Gly40Gly (120G>A)
and Ala366Ala (1098C>G) were detected. The Gly40Gly
which has not been reported previously was found in
one SALS patient and none of 200 unrelated control
individuals, indicating that it is a rare silent mutation.
The Ala366Ala which has been previously reported in
Japanese SALS patients [20] was found in one SALS
patient and one control individual, thus it was thought
to be a benign polymorphism. We also have detected a
novel polymorphism 239-18t>c in one SALS patient and
one control individual. The chromatograms of them are
shown in additional file 1.
Clinical features of the FALS patient carrying Ser292Asn
mutation
The Ser292Asn mutation was identified in a 67-year-old
male FALS patient (II2). He had some difficulty in
speech at the age of 64 and gradually presented dysar-
thria, dysphagia and atrophy of lingual muscle. One year
l a t e r ,h eb e g a nt oh a v es o m ed i f f i c u l t yi nu s i n gc h o p -
sticks and lifting his right arm, and gradually developed
weakness of both upper limbs and atrophy of muscles.
However, the fasciculation was slight. After another 4
months, he began to feel weakness in both lower extre-
mities and started having difficulties in walking up and
down stairs. Neurological examination showed muscle
weakness involving all the extremities with motor power
graded as follows: upper limbs, 3/4; lower limbs, 4/5.
However, the sensation was intact. Atrophy of lingual
muscle and distal muscles of upper limbs were evident.
There was positive Babinski sign, and the deep-tendon
reflexes were increased in both lower limbs whereas
decreased in both upper limbs. EMG testing showed
reduced amplitudes of compound muscle-action poten-
tials in right median nerve, positive sharp waves, fibrilla-
tions, and normal motor and sensory NCV. He was
treated with coenzyme Q10 60 mg daily and followed
with follow-up examinations every three months. At the
last follow-up 2 months ago, neurological examination
showed progression of disease. The powers of upper
limbs were both 2/3 grades and powers of lower limbs
were both 3/4 grades. Dysarthria and dysphagia were
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level positive airway pressure (BiPAP) and percutaneous
endoscopic gastrostomy (PEG).
Pedigree analysis of the ALS family with Ser292Asn
mutation
The pedigree of this family is shown in figure 2. The
proband’s younger brother (II5) developed right lower
limb weakness at the age of 58, and gradually extended
to muscles of both lower limbs and upper limbs. Two
years later, he developed bulbar symptoms and died of
respiratory failure at the age of 61.
Direct sequencing was performed to screen for
S e r 2 9 2 A s ni nt h ep r o b a n d ’sm o t h e r( I 2), three sisters
(II7,I I 9 and II13), one brother (II11), and their children
(III3, III5, III6, III7, III8, III11). Four of them (II7, III6, III7,
III8) were detected to have Ser292Asn. They haven’t any
clinical symptoms presently. II7 is 60 years old while
III6, III7 and III8 are less than 40 years old. Because the
85-year-old mother (I2)d o e s n ’t have Ser292Asn, we
speculated that Ser292Asn might be come from the
dead father who was asymptomatic. III6 and III7 are the
children of the dead patient (II5), thus we speculate that
Table 1 Primers designed for the TARDBP gene and conditions of PCR
Primers Oligonucleotide of primers Size of PCR product Annealing temperature
Exon2 F 5’-CTGGAAGTCAGAACTCTGAC-3’
R5 ’-TCAGGAGACATTCTGCCACC-3’
447 bp 66°C
Exon3 F 5’-GCTTCTCATTTCTAGATGTAGG-3’
R5 ’-AGAACCTAGGGAACATAGTG-3’
357 bp 58°C
Exon4 F 5’-TAAGCCACTGCATCCAGTTG-3’
R5 ’-GATTTCATGAACACACCCTG-3’
367 bp 66°C
Exon5 F 5’-TGGTTCACTGCTATCCAAGG-3’
R5 ’-AGGATGGTCTTGATCTGGTG-3’
396 bp 60°C
Exon6 F 5’-CATTGCTTATTTTTCCTCTGGC-3’
R5 ’-TATACTCCACACTGAACAAACC-3’
780 bp 62°C
Figure 1 Chromatogram of Ser292Asn (A) and conservation of Ser292Asn in different species (B).
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is unavailable for confirmation.
Discussion
The TDP-43, which is a 414-amino-amino-acid nuclear
protein encoded by TARDBP on chromosome 1p36.22,
has been identified as the major disease protein in ALS.
It is evolutionary conserved and its structure consists of a
glycine-rich domain and two RNA recognition motifs
[24]. It is known to bind DNA and RNA, such as human
immunodeficiency virus type 1 TAR DNA sequence
motifs [25], and to be involved in the regulation of mes-
senger RNA splicing and exon skipping [26]. The impor-
tance of the glycine-rich C-terminal domain of TDP-43
in mediating its exon skipping and splicing inhibitory
ability has been demonstrated and has been observed to
correlate with its ability to interact with other members
of the heterogeneous nuclear ribonuclear A and B pro-
tein families with well-known splicing inhibitory proper-
ties [27]. However, the exact function remains unclear.
Recently different pathogenic TARDBP mutations have
been described in different cohorts of patients with
FALS and SALS, supporting a direct role of TDP-43 in
neurodegeneration [9-20]. However, two additional stu-
dies by Gijselinck I et al and Guerreiro RJ et al failed to
find mutations in Belgian and North American patients
with ALS [28,29]. Among the 30 previously reported
mutations [9-20], 29 are missense mutations, and one is
frameshift mutation (Tyr374Term) which creates a pre-
mature stop codon, consequently leading to the expres-
sion of a truncated protein [17]. None of them is
homozygous. Met337Val, Gly348Cys and Ala382Thr are
the most common mutations. Additionally, except for
the Asp169Gly mutation, all other TARDBP mutations
are located in exon 6 encoding for the C-terminus of
TDP-43. Considering all the previous studies, the fre-
quency of TARDBP mutations is 3.6% in FALS and 1.0%
in SALS [16]. Most ALS patients carrying TARDBP
mutations have an Italian or French origin, suggesting a
higher frequency of TARDBP mutations in Southern
Europe (average 3.4%; 8% in France and 2.7% in Italy)
than in other Caucasian populations (average 0.7%) [16].
In the present study, after screening TARDBP muta-
tions in 71 unrelated SALS patients and probands from
5 FALS families in Chinese population, we have identi-
f i e do n em i s s e n s em u t a t ion in a FALS family and 2
silent mutations in SALS patients. This frequency is
lower than those of previous studies, which may be due
to the cohort of ALS patients analyzed here is small
compared to previous studies. Also, different races may
refer to different genetic backgrounds. The Ser292Asn
mutation was located in the highly conserved region,
exon6, encoding for the C-terminus of TDP-43. In the
FALS family with Ser292Asn, we speculated that I1 and
II5 might both carry Ser292Asn though their samples
are unavailable to the detection. The proband presented
clinical symptoms at the age of 64. However, the other
four family members (II7, III6, III7, III8) carried the same
mutation as the proband did were asymptomatic pre-
sently. III6, III7 and III8 are in their thirties and
obviously haven’t reached the onset age of ALS. II7 is 60
years old though she is clinically asymptomatic. We sug-
gest detecting EMG examination to her but she refused.
Conclusion
In conclusion, our data have extended the spectrum of
TARDBP mutations and polymorphisms, and supported
the pathological role of TDP-43 in ALS. Further studies
a r en e e d e dt os h e dl i g h to nt h e pathophysiological link
between Ser292Asn and ALS. Competing interestsThe
authors declare that they have no competing interests.
Additional file 1: Chromatograms of silent mutations (Gly40Gly and
Ala366Ala) and the novel polymorphism (239-18t>c). The normal
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